

500,446.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
10 July 2003 (10.07.2003)

PCT

(10) International Publication Number
WO 03/055475 A1(51) International Patent Classification⁷: **A61K 31/137**(21) International Application Number: **PCT/IB02/00001**

(22) International Filing Date: 3 January 2002 (03.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): **LEK PHARMACEUTICAL AND CHEMICAL COMPANY D.D.** [SL/SL]; Legal Affairs and Industrial Property, Industrial Property Department, Verovskova 57, 1526 Ljubljana (SL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JANEZ, Kerc** [SL/SL]; Trebinjska 7, 1000 Ljubljana (SL). **VLASTA, Humar** [SL/SL]; Godic 63, 1242 Stahovica (SL).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CONTROLLED RELEASE PHARMACEUTICAL FORMULATION CONTAINING VENLAFAXINE

(57) **Abstract:** A solid controlled release pharmaceutical formulation for once daily administration comprises a core comprising venlafaxine, polyvinylpyrrolidone, a low viscosity hydrophilic polymer and a high viscosity hydrophilic polymer, and a polymeric coating comprising a water high permeable polymer, and a water low permeable polymer. The invention further relates to a process for the preparation of a solid controlled release pharmaceutical formulation comprising the steps of dissolving venlafaxine and polyvinylpyrrolidone in an organic solvent, applying the resulting solution onto low viscosity polymer, homogeneously mixing the obtained granulate with a high viscosity polymer, and compressing the granulate to obtain a core which is then coated with a polymeric coating comprising a water high permeable polymer and a water low permeable polymer.



WO 03/055475 A1